Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2015

View Archived Issues

Novel markers of poor prognoses in lung adenocarcinoma

Verubecestat shows promising results as a BACE1 inhibitor

Improving methods to detect genetic variants in NSCLC

Phylogica and PhoreMost to identify small-molecule cancer drugs

Merck & Co. reports BACE1/BACE2 inhibitors

Compugen divulges anti-VSTM5 antibodies

Celprogen discloses in vivo stem cell activator

FDA approves Ethicon's fibrin sealant patch for use in liver surgery

Tricyclo-DNA antisense oligonucleotides are efficacious in mouse models of DMD

European orphan drug designation for Trappsol Cyclo transferred to MNE

Characterization of BI-409306, a PDE9 inhibitor in early-stage clinical trials

MetrioPharm receives approval to begin clinical development of MP-1032

Alligator Bioscience announces phase I trial of ADC-1013 in advanced solid tumors

Tasly Pharmaceutical patents clopidogrel derivatives

Beijing Hanmi Pharmaceutical reports BTK and/or JAK3 inhibitors

Calitor Sciences develops PI3Kdelta inhibitors

Bristol-Myers Squibb describes mGlu2 receptor PAMs

Portola Pharmaceuticals reports topline data from phase III ANNEXA-A trial

Enrollment begins in phase I/II study of ADXS-PSA in combination with Keytruda

FDA grants breakthrough therapy designation to DBV Technologies' peanut allergy treatment

Shire discloses results from first of three phase II trials of LUM-001 in Alagille syndrome

GNE-309 - a novel BTK inhibitor for the treatment of rheumatoid arthritis

Avastin approved in E.U. for treatment of advanced cervical cancer

DARPA selects Inovio Pharmaceuticals to lead Ebola virus consortium

FDA accepts ArmaGen's IND application for Hurler syndrome therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...